Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association

LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that five abstracts will be presented from the KER-050 (elritercept) program at the 29th Annual Congress of the European Hematology Association (“EHA”), to be held both virtually and in person from June 13 through 16, 2024.

The following abstracts were posted to the EHA website on May 14, 2024, 10:00 a.m. Eastern time.

Clinical Presentation

“Durable clinical treatment with elritercept (KER-050) treatment: Findings from an ongoing Phase 2 trial in participants with lower-risk MDS”

• Abstract Code: s183
• Session Title: s450 Immune and targeted therapies in MDS
• Session Date and Time: June 14, 2024; 8:45 a.m. - 10:00 a.m. Eastern time
  

“Activin A Inhibition by elritercept (KER-050) is associated with evidence of cardiovascular benefit: Translation of preclinical observations to humans with MDS”

• Abstract Code: p760
• Session Title: Poster session
• Session Date and Time: June 14, 2024; 12:00 p.m. - 1:00 p.m. Eastern time
  

“Elritercept (KER-050) demonstrated potential to treat myelofibrosis and mitigate ruxolitinib-associated cytopenias in the Phase 2 RESTORE Trial”

• Abstract Code: s223
• Session Title: s423 Clinical advances in myelofibrosis and mastocytosis
• Session Date and Time: June 15, 2024; 5:30 a.m. – 6:45 a.m. Eastern time
  

“Reduced ferritin and increased bone specific alkaline phosphatase in participants with lower-risk MDS treated with elritercept (KER-050) support potential to rebalance the osteohematopoietic niche”

• Abstract Code: s302
• Session Title: s438 Iron metabolism: From basics to the clinic
• Session Date and Time: June 15, 2024; 8:45 a.m. - 10:00 a.m. Eastern time
  

Preclinical Presentation

“RKER-050, a modified activin receptor type IIA ligand trap, rescued anemia and increased muscle mass and strength in a mouse model of myelofibrosis”

• Abstract Code: p1013
• Session Title: Poster session
• Session Date and Time: June 14, 2024; 12:00 p.m. - 1:00 p.m. Eastern time
  

About KER-050

Keros’ lead product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-ß receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (“MDS”) and in patients with myelofibrosis.